We have identified a clinically distinct subset of lupus erythematosus patients marked by the presence of a histologically proven, nonscarring variety of cutaneous LE (subacute cutaneous LE) in which there is a very high frequency of the human leukocyte antigens (HLA) B8 and DR3. Differences in the configuration of their skin lesions allowed a separation of the patients into two clinical subgroups; annular and papulosquamous. HLA-B8 was increased in the annular subgroup (81%, corrected P (Pc) < 0.007) and combined group (65%, Pc < 0.004). HLA-DR3 was present in all 11 of the annular patients (10%, Pc < 0.00008). In addition, HLA-DR3 was present in increased frequencies in the papulosquamous subgroup (60%, Pc < 0.04) and combined group (77%, Pc < 0.00008). Thus, HLA-DR3 positive individuals have a relative risk of 10.8 for developing subacute cutaneous LE of either type and an even greater relative risk (67.1) for the annular variety. The HLA phenotype A1, B8, DR3 was also found more commonly in the annular (73%, P < 0.00008) and combined patient groups (46%, P < 0.004). These HLA associations, which are stronger than ever before reported for any form of LE, did not result from the concurrent presence of subclinical Sjögren's syndrome. Thus, subacute cutaneous LE can now be added to the growing list of HLA-B8, DR3-associated diseases that […] 
A B S T R A C T We have identified a clinically distinct subset of lupus erythematosus patients marked by the preseinee of' a histologically proven, noniscarring variety of cutaineous LE (subacute cutaneous LE) in which there is a very high frequency of the human leukocyte antigens (HLA) B8 and DR3. Differences in the configuration of their skin lesions allowed a separation of the patients into two clinical subgroups; annular and papulos(luamiious. HLA-B8 was increased in the annular subgroup (81%, corrected P (Pc) < 0.007) and combined group (65%, Pc < 0.004). HLA-DR3 was present in all 11 of the annular patients (100%, Pc < 0.00008). In addition, HLA-DR3 was present in increased frequencies in the papulosquamous subgroup (60%, Pc < 0.04) and combined group (77%, Pc < 0.00008). Thus, HLA-DR3 positive individuals have a relative risk of 10.8 for developing subacute cutaneous LE of either type and an even greater relative risk (67.1) for the annular variety. The HLA phenotype Al, B8, DR3 was also found more commonly in the annular (73%, P < 0.00008) and combiined patient groups (46%, P < 0.004). These HLA associations, which are stronger than ever before reported for (1, 2) have established that genetic factors exist in LE and an abnormality in immune regulation in relatives of LE patients was recently reported (3) . Because of the evidence in animals that suggests that immune responsiveness (4) and some forms of autoimmunity (5) are under genetic control of the main histocompatibility complex it has been speculated that LE results from an interaction of genetic, immunologic, and environmental factors (6) . However, data to support the hypothesis that predisposition for development of LE is based on main histocompatibility complex determined disorder of indicate that an association with certain genes of the HLA system exists in this subset ofLE patients which is stronger than any previously observed association in patients with LE.
METHODS
Patient selection. 26 patients with histologically confirmed SCLE as previously defined (16), who were available for HLA typing, were included in the present study. 11 patients were common to both the present study group and the original group reported (16) . Based on the configuration of their skin lesions these patients could be divided into annular and papulosquamous subgroups (16) . There were 11 patients in the annular group and 15 in the papulosquamous group. All patients were examined by Dr. Sontheimer and Dr. Gilliam and were categorized as either annular or papulosquamous before laboratory testing or HLA typing studies were carried out.
HLA typing. HLA-A, -B and -DR type were determined serologically by methods that have been previously described (17) . The patients were tested for 19 HLA-A, 31 HLA-B, and 8 HLA-DR antigens. Our normal controls were all Caucasoids, living in the same geographic area as the SCLE patients and typed in our laboratory using the same reagents. The HLA data were analyzed for significance by the chisquare test with the Yates' correction. The P values obtained were corrected by multiplying by the number of antigens determined at the locus (Pc). The relative risks (RR) were calculated by either the formula of Woolf or that of Haldane as appropriate.
Evaluation for Sjogren's syndrome. 17 of the SCLE patients completed a questionnaire in which five questions were asked regarding the presence or absence of dry eyes or dry mouth. An affirmative response to at least three of the five questions was considered significant. Shirmer's tests before and after local pontocaine anesthesia were completed in 15 of the same patients. Less than 10 mm of filter paper wetting before local anesthesia was considered to reflect a significant decrease in the rate of reflex tear production. Less than 5 mm after local anesthesia was considered to reflect a significant decrease in the basal tear secretion rate. Slit lamp and fluorescein staining examinations were also completed in these 15 patients. Nine patients agreed to have punch biopsies taken from the mucosa of the lower lip which were evaluated histologically by standard methods.
RESULTS
Clinicalfeatures. The mean age of the entire group was 41+±13 yr, with a range from 21 to 73 yr. 21 were female and 5 were male. All patients were Caucasoid. The age and sex distribution of the annular and the papulosquamous subgroups were not significantly different. 14 patients (54%) had four or more of the preliminary American Rheumatism Association (ARA) criteria for classification as systemic LE (seven annular and seven papulosquamous). If the three cutaneous ARA criteria (facial erythema, discoid lesions, and photosensitivity) were excluded, then only five patients had four or more ARA criteria (one annular and four papulosquamous). SCLE has been present in -10% of the LE patients seen by us over the past 10 yr.
HLA typing. As shown in Table I , Al was the only HLA-A antigen that was significantly increased in frequency, occurring in 8 of the 11 annular SCLE patients (Pc < 0.05). HLA-B8 was significantly increased in frequency in the annular (81%, Pc < 0.007) and combined patient groups (65%, Pc < 0.004). Although HLA-B8 was increased in frequency in the papulo- 
DISCUSSION
A number of workers have demonstrated weak but statistically significant HLA associations in different populations of SLE patients. HLA-Al was found to be present in 14% of black SLE patients in one study (7) . HLA-B5 was seen in 23% of black American SLE patients in another study (8) . HLA-B8 has been found in 33% (9), 48% (10), and 59% (11) of different SLE populations. HLA-B15 has been seen in 46% (12) and 40% (9) of SLE patient groups. HLA-DR2 has been found in 57% (13) and 50% (14) of SLE patient groups and finally, HLA-DR3 has been seen 46% (13), 54% (14) , and 39% (15) of different SLE populations. The HLA-B8 (65%) and -DR3 (77%) frequencies that we have found in our SCLE patients are higher than have been previously reported in these other LE populations. Indeed, the presence of HLA-DR3 in all 11 of our annular SCLE patients is among the strongest HLAdisease associations yet reported. Since We have not found significant HLA associations in another form of cutaneous LE, chronic scarring discoid LE (21). Millard et al. (22) have found an increased incidence of HLA-B7 and HLA-B8 in discoid LE patients. In addition, they have reported that female patients with discoid LE who are HLA-B8 positive are more likely to develop SLE than HLA-B8-negative female DLE patients. It is not clear from their report whether or not they classify SCLE as a form of discoid LE or as a feature of SLE. We have seen several patients who initially presented with typical localized scarring discoid LE lesions and later developed SCLE with systemic LE activity.
Several groups have found that SLE patients who have the HLA-Al, B8 phenotype are more likely to have severe systemic disease activity, particularly nephropathy (7, 23) . Our findings do not support this concept. SCLE tends to occur in patients who generally have a more benign form of LE. The incidence of severe central nervous system or renal involvement is lower in this subset compared to that of unselected SLE populations (16) . The HLA-A1, B8, DR3 phenotype was present in 8 of the 11 annular SCLE patients (73%) and only 4 of the 15 papulosquamous patients (27%). The annular SCLE patients tend to have even milder types of systemic illness than the papulosquamous patients.
That subset of LE patients who have SCLE can now be added to the growing list of organ specific autoimmune conditions that are associated with the HLA-B8,DR3 phenotype. These conditions include SS (18, 19, 24) , Graves' disease (25) , juvenile onset diabetes mellitus (26) , Addison's disease (26) , Celiac disease (27) , dermatitis herpetiformis (28) , chronic active hepatitis of the juvenile type (29) , idiopathic membranous nephropathy (30) , and myasthenia gravis (31) . One of the unifying features in all of these conditions could be a state of heightened immune responsiveness to either self or foreign antigenic stimulation. Thus, the tissue injury that occurs at the dermalepidermal junction in SCLE might result from a genetically programmed state of cellular immune hyperresponsiveness to antigens normally elaborated in and released from the epidermis. For example, native DNA or ultraviolet light altered-DNA could be such antigens. It is also possible that the relevant epidermal antigen could be a foreign one such as a yet unidentified virus. We are currently investigating these possibilities.
